HCW Biologics Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
HCWB$0.95-6.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of changes in stockholders’ equity (deficit)
Condensed Statements of Changes in Stockholders’ Equity (Deficit)
For the Three Months Ended March 31, 2025 and 2026
| Stockholders’ Deficit | |||||
|---|---|---|---|---|---|
| Common Stock · Additional Paid-In · Accumulated · Total Stockholders’ | |||||
| Shares | Amount | Capital | Deficit | Deficit | |
| Balance, January 1, 2025 | 1,113,532 | $111 | $93,785,854 | $(100,556,137) | $(6,770,172) |
| Issuance of Common Stock upon exercise of stock options | 205 | 1 | 1,653 | — | 1,654 |
| Issuance of Common Stock to Square Gate | 9,615 | 1 | 149,999 | — | 150,000 |
| Issuance cost of Common Stock | — | — | (22,297) | — | (22,297) |
| Stock-based compensation | — | — | 275,642 | — | 275,642 |
| Net loss | — | — | — | (2,196,875) | (2,196,875) |
| Balance, March 31, 2025 | 1,123,352 | $113 | $94,190,851 | $(102,753,012) | $(8,562,048) |
| Stockholders’ Equity | |||||
|---|---|---|---|---|---|
| Common Stock · Additional Paid-In · Accumulated · Total Stockholders’ | |||||
| Shares | Amount | Capital | Deficit | Equity | |
| Balance, January 1, 2026 | 3,279,812 | $328 | $111,280,287 | $(108,515,846) | $2,764,769 |
| Common Stock issued in connection with abeyance shares (1) | 977,000 | 98 | (98) | — | — |
| Issuance of pre-funded warrants | — | — | 1,499,753 | — | 1,499,753 |
| Exercise of pre-funded warrants | 2,477,292 | 247 | — | — | 247 |
| Reclassification of the modified warrant to liability | — | — | (1,595,778) | — | (1,595,778) |
| Issuance of Common Stock warrants and repricing of modified warrants | — | — | 1,488,472 | — | 1,307,609 |
| Equity dividend to investor | — | — | (1,488,472) | — | (1,307,609) |
| Issuance costs of Common Stock warrants | — | — | (181,198) | — | (181,198) |
| Issuance costs of pre-funded warrants | — | — | (207,858) | — | (207,858) |
| Stock-based compensation | — | — | 10,019 | — | 10,019 |
| Net income | — | — | — | 3,472,480 | 3,472,480 |
| Balance, March 31, 2026 | 6,734,104 | $673 | $110,805,127 | $(105,043,366) | $5,762,434 |
| (1) | During the three months ended March 31, 2026, 977,000 shares previously held in abeyance were issued and there are no shares in abeyance remaining. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.